兴齐眼药：SQ-129玻璃体缓释注射液获临床试验批准

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of SQ-129, a vitreous body sustained-release injection aimed at treating diabetic macular edema (DME) and macular edema caused by branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) [1] Summary by Categories Product Development - SQ-129 is classified as a Class 2 modified new chemical drug and has completed various studies including pharmaceutical and non-clinical pharmacology and toxicology, demonstrating good safety and clinical development value [1] - There are currently no approved products of this kind available in the domestic and international markets [1]